HAVE WE SHIFTED OUR PARADIGM OF CLOPIDOGREL AS A MANDATORY DRUG IN TREATMENT OF CARDIOLOGICAL PATIENTS AFTER THE INTRODUCTION OF MORE POWERFUL ANTIAGREGANTS?

Abstract

Despite the decline in cardiovascular mortality rate in recent decades due to the widespread use of antihypertensive, hypocholesterolemic and antiplatelet drugs, various manifestations of ischemic heart disease (IHD) retain one-third of the mortality pattern in individuals older than 35 years [1–3]. In regions with a developed health system, cardiovascular mortality is gradually declining. However, death from various manifestations of IHD remains the leading cause of death among adults regardless of income level [4].

Keywords

• arterial thrombosis
• antiaggregants
• clopidogrel